Behring sales up 16% despite economic climate:
This article was originally published in Clinica
Behring Diagnostics, a subsidiary of German group Hoechst, has reported a 16% sales increase to DM 930 million ($620 million) in 1996. Sales in Behring's main markets - the US, Germany and Japan - continue to be hit by cost-cutting measures and the poor economic climate. However, significant growth was achieved in the rest of Asia, the Middle East and Eastern Europe. In March, Behring Diagnostics and Dade International announced their intention to merge. The companies are awaiting approval from the US and European authorities (see Clinica No 748, p 1).
You may also be interested in...
Public Company Edition: Lixte’s small uplisting was the only biopharma initial public offering in the US during Thanksgiving week, but IPOs are ramping up again. Also, LifeSci launched its second SPAC and in follow-on offerings Reata brought in $281m and Intellia grossed $175m.
Orladeyo is the first oral prophylactic approved in the US for hereditary angioedema, with Japan and EU approvals expected to follow. Pricing of $485,000 a year undercuts segment leader.
Results of Study to Assess Statin Residual Risk with Epanova in High Cardiovascular Risk Patients with Hypertriglyceridemia “should prompt reconsideration of [OTC] mixed omega-3 fatty acid products for [atherosclerotic cardiovascular disease] prevention,” say cardiologists in an editorial published with JAMA study.